Elanco Animal Health (NYSE:ELAN) Director Michael Harrington Buys 5,000 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Michael Harrington bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director owned 131,451 shares of the company’s stock, valued at $2,868,260.82. This trade represents a 3.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Elanco Animal Health Stock Up 1.8%

NYSE:ELAN opened at $22.52 on Friday. The firm has a market capitalization of $11.25 billion, a price-to-earnings ratio of -54.93, a PEG ratio of 1.33 and a beta of 1.67. Elanco Animal Health Incorporated has a 1-year low of $17.11 and a 1-year high of $27.98. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The business’s fifty day moving average price is $24.56 and its 200 day moving average price is $24.03.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period last year, the company posted $0.26 EPS. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ELAN. JPMorgan Chase & Co. increased their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. TD Cowen increased their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Morgan Stanley boosted their target price on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 22nd. Finally, UBS Group upped their target price on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.09.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds have recently bought and sold shares of ELAN. BlackRock Inc. bought a new stake in Elanco Animal Health during the second quarter worth approximately $1,202,198,000. UBS Group AG boosted its holdings in shares of Elanco Animal Health by 56.7% during the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Sei Investments Co. boosted its holdings in shares of Elanco Animal Health by 737.5% during the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Elanco Animal Health by 336.0% in the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after acquiring an additional 3,690,735 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.